ABSTRACT
INTRODUCTION
Fibroblast-to-myofibroblast phenoconversion in the heart is a crucial event in the onset of many cardiovascular diseases. Cardiac fibroblasts are an understudied cell, despite the fact that they constitute the majority of cells in the heart (Weber and Brilla, 1991) . These relatively quiescent cells reside in the cardiac interstitium and synthesize cardiac fibrillar collagen types (e.g. types I and III), as well as the majority of other extracellular matrix proteins.
Cardiac stress and injury both induce differentiation of fibroblasts into hypersecretory and contractile myofibroblasts, which can persist in the myocardium for months (and even years) after the initial pathological insult (Willems et al., 1994) . The myofibroblast is associated with fibrillar collagen deposition, leading to reduced cardiac efficiency and, ultimately, decompensated heart failure. Initially, increased collagen deposition is beneficial, but when left to persist for years, it can transform healthy myocardium with normal extracellular matrix complement into overtly fibrosed tissue with abnormal expansion of the interstitium (Freed et al., 2005) .
Fibroblast-to-myofibroblast phenoconversion is marked by increased expression of a-smooth muscle actin (a-SMA) (Darby et al., 1990) , extra domain A (ED-A) fibronectin (Serini et al., 1998) , and non-muscle myosin heavy chain b (SMemb) (Frangogiannis et al., 2000) . Although not well understood, this process is typically thought of as being a 'one-way' pathway. However, Hinz and colleagues have provided data that both forward and reverse phenoconversion are possible in these cells, depending upon the compressibility of the underlying substrate (Hinz et al., 2001) . Still, the molecular mechanisms for fibroblast-myofibroblast inter-conversion have yet to be fully elucidated.
The canonical TGF-b signaling cascade has been implicated as an important inducer of phenoconversion. High levels of this cytokine are associated with cardiac fibrosis (Brooks and Conrad, 2000) . The diverse functions of TGF-b necessitate the tight control of membrane-to-nucleus signal transduction; in particular, levels of the endogenous inhibitors Smad7 and Ski. The protooncoprotein Ski has a complex set of functions and is linked to skeletal muscle hypertrophy (Sutrave et al., 1990a; Sutrave et al., 1990b) , as well as developmental defects in the neural tube and cranial mesenchyme (Berk et al., 1997) . Ski binds to R-Smad proteins (Sun et al., 1999; Suzuki et al., 2004; Ueki and Hayman, 2003; Xu et al., 2000) and might inhibit TGF-b-mediated effects through both nuclear and cytosolic mechanisms (Akiyoshi et al., 1999; Ferrand et al., 2010; Nagata et al., 2006; Suzuki et al., 2004) . We have previously demonstrated the anti-fibrotic and anti-contractile effects of overexpression of Ski in TGF-b1-stimulated primary cardiac myofibroblasts, and have shown these inhibitory effects to be orchestrated at the nuclear level (Cunnington et al., 2011) .
Mesenchyme homeobox 2 (Meox2, also known as growth arrest specific homeobox protein, Gax) and Meox1 comprise the Meox family of homeodomain proteins. Meox1 and Meox2 proteins share 95% sequence identity within the homeodomain region, but are otherwise highly divergent (Douville et al., 2011) . Both Meox1 and Meox2 are required for proper bone and muscle formation in developing mouse embryos (Mankoo et al., 1999; Mankoo et al., 2003) . Meox2 expression is decreased by mitogen stimulation of vascular smooth muscle cells (Gorski et al., 1993) and in mechanically damaged arteries (Weir et al., 1995) , indicating that Meox2 expression is sensitive to a range of stimuli. Meox2 could enhance TGF-b-mediated inhibition of cell proliferation (Valcourt et al., 2007) or, conversely, might block TGF-b-induced epithelial-to-mesenchymal transition (EMT) (Valcourt et al., 2007) . Meox2 expression is repressed by the Zeb2 protein [also called Smad-interacting protein 1 (Sip1 or Zfhx1b)], a zinc-finger E-box binding protein (Chen et al., 2010) . Zeb2 expression itself has been shown to be positively regulated by TGF-b signaling during EMT (Comijn et al., 2001) .
In this study, we provide data to support a novel mechanism through which Ski regulates the cardiac fibroblast phenotype. We show for the first time that both Meox1 and Meox2 are downregulated during fibroblast-to-myofibroblast phenoconversion, and that overexpression of Ski can rescue Meox2 expression. Moreover, our data establish a link between increased Meox2 expression and a reduction of the myofibroblast phenotype. Finally, we identify a putative signaling cascade that might modulate fibroblast-to-myofibroblast phenoconversion through the differential expression of Ski, Zeb2 and Meox2 proteins.
RESULTS

Meox1 and Meox2 are downregulated during phenoconversion
Marker proteins frequently used to monitor fibroblast-tomyofibroblast phenoconversion include an increase in expression of a-SMA (Darby et al., 1990) , ED-A fibronectin (Serini et al., 1998) and SMemb (Frangogiannis et al., 2000) . Myofibroblasts in the infarct scar can arise from a range of different processes, e.g. fibroblast migration (Gabbiani, 1996) , differentiation of bone marrow progenitor cells (Möllmann et al., 2006; van Amerongen et al., 2008) and EMT (van Tuyn et al., 2007; Zhou et al., 2010) . Because Meox2 is associated with inhibition of TGF-b1-induced EMT (Valcourt et al., 2007) , we examined the potential link between Meox2 and induction of the myofibroblast phenotype in rat primary cardiac fibroblasts, and in first and second passage myofibroblasts. To our knowledge, Fig. 1 . The role of Meox1 and Meox2 in cardiac fibroblast-to-myofibroblast phenoconversion. (A) Meox1 and Meox2 mRNA levels are reduced during fibroblast-to-myofibroblast differentiation. RNA was harvested from P0, P1 and P2 cells and used for qPCR. GAPDH primers served as a control for loading. The data shown were obtained from n53 independent experiments. *P,0.005. (B) Primary fibroblasts (P0) and first (P1) and second (P2) passage myofibroblasts were isolated, total protein prepared, and Meox2 protein expression examined by western blot using a-tubulin as a loading control. Representative western blots for Meox2 and a-tubulin protein expression are shown above the histograms for Meox2 protein expression. The data shown are from n53 independent experiments; *P,0.01 versus P0. Error bars represent s.e. (C) Cryosections of 4-week post-MI rat heart tissue were stained for Meox2 (green) and Vimentin (red) with DAPI nuclear stain (blue). Images are representative of n53 hearts.
Meox1, which is closely related to Meox2, has not been implicated in EMT or TGF-b1 signaling. Therefore, we also examined its putative role in fibroblast-to-myofibroblast phenoconversion. We observed a 96% and 99% downregulation of Meox2 mRNA expression during the phenoconversion (Fig. 1A ) of primary fibroblasts (P0) to first and second passage myofibroblasts (P1 and P2), respectively. Levels of Meox1 mRNA decreased with increasing passage in an identical manner to that of Meox2 (Fig. 1A) . Western analysis demonstrated that Meox2 protein expression is also significantly decreased during fibroblast-tomyofibroblast phenoconversion (Fig. 1B) .
Meox2 expression is decreased in post-myocardial-infarct scar
To assess the relevance of Meox2 expression to the myofibroblast phenotype in vivo, we performed immunohistochemistry on hearts 4 weeks after myocardial infarct (MI) (Fig. 1C) . Vimentin staining (red color in composite) intensity was increased in the infarct scar region, showing the predominance of mesenchymal cells (e.g. myofibroblasts) in the infarct scar. We observed a substantial reduction in Meox2 staining (green color in composite) in the scar portion of the heart compared with the remnant heart. Nuclei were stained with DAPI (blue color).
Meox2, but not Meox1, overexpression diminishes the myofibroblast phenotype Because expression of Meox1 and Meox2 mRNA is downregulated during fibroblast-to-myofibroblast differentiation, we hypothesized that re-introduction of these proteins in first passage myofibroblasts would restore the fibroblastic phenotype. Using an adenoviral system for overexpression of Meox1 and Meox2, we observed that Meox2 was able to reduce the expression of the myofibroblast markers a-SMA and ED-A fibronectin ( Fig. 2A,B) . By contrast, Meox1 had no effect on expression of these markers (Fig. 2) . Notably, overexpression of Meox1 or Meox2 did not affect SMemb expression (Fig. 2) . Finally, overexpression of a DNA-bindingdeficient version of Meox2 (Meox2DBDmt) (Douville et al., 2011) was unable to alter the myofibroblast phenotype (Fig. 2C,D) .
Meox2 overexpression induces myofibroblast proliferation
We have previously shown that Meox2 expression induces cell cycle arrest and senescence in vascular endothelial cells (Douville et al., 2011) . However, in cardiac myofibroblasts, overexpression of Meox2 induces significant (P,0.01, P,0.001) proliferation (Fig. 3) , indicating that Meox2-mediated effects on cellular proliferation are dependent on the cell type. Ski diminishes, but does not fully reverse, the myofibroblast phenotype
Our lab has previously shown the ability of Ski overexpression to diminish expression of the myofibroblast phenotypic marker a-SMA in first passage myofibroblasts (Cunnington et al., 2011) . To extend this finding, we tested the expression of additional markers of phenoconversion by western analysis. Following Ad-Ski transduction for 24 hours, we observed that Ski overexpression was able to significantly reduce expression of ED-A fibronectin, yet had no effect on the expression of SMemb (Fig. 4) , as we had observed following overexpression of Meox2 (Fig. 1C,D) . Thus, although the fibroblastic phenotype was not fully restored, the myofibroblastic phenotype was significantly diminished.
Ski increases expression of Meox2 but not Meox1 mRNA
Given the identical effects of overexpression of Ski and Meox2 on diminution of the myofibroblast phenotype, we hypothesized that a link might exist between these two proteins. We therefore transduced first passage cardiac myofibroblasts with Ad-Ski and then measured the mRNA expression levels of Meox1 and Meox2 with and without TGF-b1 stimulation (10 ng/ml for 24 hours). In the absence of TGF-b1 stimulation, Ad-Ski overexpression resulted in a ,5.5-fold increase in Meox2 mRNA expression levels over controls, but produced no discernible effect on levels of Meox1 (Fig. 5) . Following TGF-b1 stimulation, Meox1 mRNA levels were, again, unaltered, whereas those of Meox2 increased ,7.5-fold above control levels. However, this increase was not found to be significantly different when compared with the Meox2 levels attained by Ad-Ski overexpression in the absence of TGF-b1 stimulation (Fig. 5 ).
Zeb2 expression increases during fibroblast-tomyofibroblast differentiation
As downregulation of Meox2 mRNA and protein is associated with phenoconversion, we examined the potential role of Zeb2 (a repressor of Meox2 transcription), in fibroblast-to-myofibroblast differentiation. Proteins were isolated from primary cardiac fibroblasts and first and second passage myofibroblasts, and tested for Zeb2 protein expression. We observed a significant upregulation of Zeb2 protein in P1 and P2 myofibroblasts compared with primary fibroblasts (Fig. 6A,C) .
Overexpression of Ski reduces Zeb2 expression
As the Zeb2 protein has been shown to repress Meox2 expression in human umbilical vein endothelial cells (Chen et al., 2010) , we examined Ski-overexpressing cells for Zeb2 protein expression. Following 48 hours of incubation with Ad-Ski, we observed a significant reduction in Zeb2 protein expression, compared with non-transduced and Ad-LacZ-transduced P1 myofibroblasts (Fig. 6B,D) . These data provide a link between Ski, Zeb2 and Meox2 expression levels in modulating cardiac fibroblast or myofibroblast phenotype.
Meox2 levels decrease whereas Zeb2 increases in cytoplasm following myocardial infarction
We have previously shown that Ski accumulates in the cytoplasm after myocardial infarction (Cunnington et al., 2011) . We examined Meox2 and Zeb2 expression in an in vivo coronary ligation model of MI. We observed a significant decrease in Meox2 expression in the cytosolic fraction at 48 hours and 4-week post-MI scar portion of the heart compared with sham and viable tissue. Although expression of Meox2 at 2 weeks post-MI also decreased in the scar, the change was not significant (Fig. 7) . Zeb2 expression was significantly increased in the cytosolic fractions 48 hours and 2 weeks post-MI, but was decreased at 4 weeks post-MI in the scar portion of the heart compared with sham heart and viable tissue (Fig. 7) .
DISCUSSION
Cardiac fibroblast-to-myofibroblast phenoconversion constitutes an important area of investigation because of the long-term deleterious consequences of chronic fibrosis in the heart. However, the mechanism(s) by which this phenomenon occurs is/are poorly understood. Myofibroblasts arise in the heart in response to the stress or injury associated with MI, hypertension and diabetic cardiomyopathy, as well as other cardiomyopathies (González-Vilchez et al., 2005; González et al., 2002; Ihm et al., 2007; Pelouch et al., 1993) . These cells contribute to inappropriate myocardial remodeling that is characterized by the deposition of excessive fibrillar collagens, which impair overall cardiac function and hasten the progression into heart failure. Myofibroblasts persist in the injured heart for years (Willems et al., 1994) and the mechanism for the rescue of the quiescent fibroblastic phenotype in vivo has yet to be determined.
The importance of mechanical tension in regulating fibroblastmyofibroblast differentiation has been shown in vitro and in vivo (Hinz et al., 2001; Wang et al., 2003; Arora et al., 1999) . Others have also identified stretch as being a modulator of myofibroblast phenotype (Thayer et al., 2011) . Additional factors have been shown to affect myofibroblast phenotype, for example, Wnt3a signaling (Carthy et al., 2011) . Knowledge of the precise mechanisms mediating this process is vital to create an effective treatment for fibrotic diseases of the heart.
In this study, we have identified a novel signaling pathway that regulates the differentiation of primary cardiac fibroblasts to myofibroblasts (Fig. 8) , and highlights the involvement of three proteins that are associated with phenoconversion: Ski, Meox2 and Zeb2. Here, we provide evidence that Ski derepresses Meox2 by repression of Zeb2 to reduce the myofibroblast phenotype (i.e. a-SMA and ED-A fibronectin expression) and, taken with our previous study (Cunnington et al., 2011) thereby reduces collagen synthesis and secretion, and contracture. cardiac myofibroblasts were either transduced with Ad-LacZ (100 MOI) or Ad-HA-Ski (100 MOI), or not transduced (control). Cells were serum-starved for 24 hours and then were either left untreated or were stimulated with TGFb1 (10 ng/ml for 24 hours). Total RNA was isolated and one-step qPCR was performed with Meox1 and Meox2 primers. GAPDH primers were used to control for loading. *P,0.005 versus control. The data shown are from n54 independent experiments. Error bars represent s.e. Fig. 3 provides evidence that Meox2 overexpression induces cardiac myofibroblast proliferation. We postulate that the finding of decreasing myofibroblast marker expression does not reflect a hypoproliferation of cells. Rather, this indicates the decreased averaged expression of cardiac myofibroblast markers from each cell en masse. Seminal work by Gabbiani and colleagues has led to the well-accepted tenet that transition from the so-called fibroblastic phenotype to a differentiated supermature myofibroblast is not defined as an on-off event, but is a continuum (Desmoulière et al., 2005) . Thus, one might observe altered expression of salient markers and proliferative capacity in cells that retain the relative contractility and hypersecretory characteristics of myofibroblasts. Although they might not be supermature myofibroblasts, they retain high expression of the specific markers. Whereas Gabbiani and co-workers carried out their work largely in skin myofibroblasts, we have extended this work to cardiac myofibroblasts (Santiago et al., 2010) , which showed a similarly detailed graded expression of myofibroblastic markers both in vivo and in vitro. Further, in our studies on Ski (Cunnington et al., 2011) , we found that Ski acts a molecular rheostat to 'dial back' the expression of salient markers for myofibroblasts in these cells. Thus, we conclude that the results in Fig. 3 represent increased proliferation of a population with an intermediate phenotype, which are still categorized as myofibroblasts.
In addition to the changes in protein levels typically observed with the more commonly used indicators of fibroblast-tomyofibroblast phenoconversion (i.e. a-SMA, ED-A fibronectin and SMemb) (Darby et al., 1990; Frangogiannis et al., 2000; Serini et al., 1998) , we show that Meox1 and Meox2 mRNA levels are downregulated during phenoconversion. Our observation that a loss of Meox2 protein is associated with phenoconversion suggests that it might be important in maintaining the quiescent phenotype. Moreover, increased Zeb2 protein expression, which is associated with increasing passage number, points to a direct molecular mechanism for the downregulation of Meox2 and subsequent change in cellular phenotype. Thus, Meox2 and Zeb2 form part of a signal cascade that is regulated by Ski, and drives the differentiation of fibroblasts into hypersynthetic myofibroblasts (Fig. 8) . Although fibroblast-to-myofibroblast phenoconversion is a complex process that probably requires myriad signals to proceed, our current results shed light on the nature of these pathways.
If treatment of primary cells with Ski or Meox2 adenoviruses were enriching a fibroblast population (as opposed to reducing myofibroblast phenotype) then the expected result would be a decrease in all myofibroblast markers. Our results do show a decrease in a-SMA and ED-A fibronectin, but do not show a significant change in SMemb (a third myofibroblast marker). We interpret this result to indicate a diminution of the myofibroblast cell phenotype rather than an enrichment of a fibroblast sub-population.
Transduction with Ad-Ski or Ad-Meox2 was able to partially reverse the myofibroblastic phenotype as indicated by a reduction in a-SMA and ED-A fibronectin expression levels. However, exogenous application of these two proteins could not fully restore the fibroblastic phenotype, as characterized by steady levels of SMemb. Thus, we interpret this finding as indicating that the cells convert to a proto-myofibroblastic phenotype. Although Meox1 and Meox2 share a high degree of amino acid sequence identity within their homeodomains, they are otherwise quite divergent from each other (Douville et al., 2011) . Therefore, the observation that Meox1 and Meox2 did not exert the same effects on P1 myofibroblasts was not necessarily surprising. Meox1 mRNA expression was dramatically reduced in first passage myofibroblasts compared with primary fibroblasts. However, overexpression of this protein did not modulate the expression of any of the myofibroblastic phenotype markers analyzed. However, Meox1 might affect the expression of other proteins related to phenoconversion that were not examined in this study. Alternatively, Meox1 might not directly affect the fibroblast or myofibroblast phenotype at all, but is simply downregulated as a 'side effect' of other mechanisms operating during the process of phenoconversion. The DNA-binding-deficient version of Meox2, Meox2DBDmt, was also unable to elicit changes in myofibroblast phenotype, indicating that an interaction of Meox2 with DNA is necessary to alter the gene expression patterns that are essential for a diminished myofibroblastic phenotype. The mechanism of these changes is currently unknown.
We found that Ski, Meox2 and Zeb2 are relatively unregulated in viable, noninfarcted tissues at various times following myocardial infarction, and that regulation is significant in the infarct scar in the viable region with these three genes at many of the times assessed in the data from these two different papers. As we know that the infarct scar is populated mainly by myofibroblasts in the infarct scar (Santiago et al., 2010) , and the viable cardiac tissue is composed of at least four different cell types, including cardiac myocytes, we expect the diversity of cell types might be at the basis of this disparity between regions. This cumulative finding might also point to the existence of another regulatory network that is specific to the viable region.
In subcellular fractionation experiments designed to detect cytosolic Meox2, we observed a significant reduction of expression in early (48 hour) and late (4 week) time points following myocardial infarction (Fig. 7) . In contrast, Zeb2 was significantly elevated in early (48 hours and 2 weeks post-MI) and reduced in late stage (4 weeks post-MI) relative to shamoperated and viable sample averages. These contrasting expression patterns are consistent with our model of signaling response following myocardial injury (Fig. 8) . Furthermore, our immunofluorescence data on infarcted rat heart revealed a striking relative reduction of Meox2 (Fig. 1C) , which might underscore the pathophysiological relevance of this pathway in this model of human heart disease, because the infarct scar is populated by myofibroblasts (Santiago et al., 2010) .
In the infarct scar, we found evidence for elevated cytosolic Zeb2. This finding might indicate a new mechanism for Zeb2-mediated regulation of Meox2. For example, Zeb2 could be decreasing Meox2 indirectly by sequestration to the cytoplasm of transcriptional activators of Meox2 expression, much as C184M Fig. 8 . Model of the signaling pathway for Ski modulation of myofibroblast phenotype. We have previously demonstrated that overexpression of Ski leads to decreased collagen secretion in cardiac myofibroblasts. Based on the data generated in the current study, we propose that Ski represses expression of the Zeb2 protein through unknown mechanisms (bottom). Inhibition of Zeb2 protein then de-represses Meox2, thereby partially restoring the fibroblastic phenotype and decreasing myofibroblastic function (e.g. collagen type I synthesis/secretion). After injury (top), we suggest that cytosolic movement of Ski is causal to elevated Zeb2 expression and repression of Meox2, thus facilitating fibroblast-tomyofibroblast phenoconversion.
sequesters receptor-activated Smad2 (Kokura et al., 2003) . The elucidation of this possible regulatory mode will be an object of our future studies.
We have previously shown that expression of Ski increases as fibroblasts phenoconvert into myofibroblasts, both in culture and during cardiac remodeling following myocardial infarction (Cunnington et al., 2011) . This result might seem counterintuitive in relation to the observed effect of exogenous Ski application decreasing Zeb2 expression and diminishing the myofibroblast phenotype. However, in the infarct scar, localization of Ski shifts from nuclear to cytoplasmic during the progression of cardiac remodeling and the associated fibroblastto-myofibroblast phenoconversion (Cunnington et al., 2011) . Ad-Ski localizes to the nucleus and causes diminution of myofibroblast phenotype. Thus, Ski localization is important in determining its function. Within the nucleus, we propose that Ski, by inhibiting Smad signaling, inhibits Zeb2 production, thus maintaining an elevated level of Meox2 that helps to keep the fibroblast in a quiescent state. When Ski translocates to the cytosol, however, the mechanisms required to maintain the quiescent phenotype are disabled and the cell differentiates into a myofibroblast. Thus, nuclear Ski may act as a cellular 'brake' in preventing differentiation of fibroblasts to myofibroblasts through its ability to inhibit Zeb2 expression, thereby relieving the inhibitory influence of Zeb2 on Meox2 expression levels. In the damaged heart, however, that 'brake' might be released by the shuttling of Ski from the nucleus to the cytosol.
Understanding the specific mechanisms that orchestrate fibroblast-to-myofibroblast phenoconversion is critical in developing effective strategies for the treatment of fibrotic heart disease. The current results outline a novel signaling pathway that regulates phenoconversion between cardiac fibroblasts and myofibroblasts.
MATERIALS AND METHODS
Cell isolation and culture
Cardiac fibroblasts were isolated as described previously (Hao et al., 2000) . Briefly, hearts from adult male Sprague-Dawley rats (150-200 g) were subjected to Langendorff perfusion with DMEM-F12 (Gibco, Carlsbad, CA) followed by SMEM (Gibco, Carlsbad, CA). Perfused hearts were digested with 0.1% w/v collagenase type 2 (Worthington) in SMEM for 20 minutes, removed from the Langendorff apparatus, and minced/triturated in dilute collagenase solution (0.05% w/v) for 15 minutes before addition of growth medium [DMEM-F12 supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin (Gibco, Carlsbad, CA), 100 mg/ml streptomycin (Gibco) and 1 mM ascorbic acid (Sigma, St Louis, MO)]. Upon settling of large tissue pieces in a 50 ml conical tube, the supernatant was recovered and centrifuged at 750 g for 5 minutes. Cell pellets were resuspended in growth medium and plated in 75 cm 2 culture flasks. Cells were allowed to adhere for 2-3 hours in a 5% CO 2 incubator at 37˚C, then washed twice with phosphate-buffered saline (PBS) followed by the addition of fresh growth medium. The medium was changed the following day and cells allowed to grow for 3-4 days before passaging into P1 myofibroblasts. P1 myofibroblasts were infected with adenovirus at the time of plating. Transforming growth factor beta 1 (TGF-b1) cytokine (Cell Signaling, Danvers, MA) (10 ng/ ml) treatment was applied to cells following a 24 hour period of serum starvation.
Adenoviral constructs
Generation of the HA-Ski adenoviral vector was previously described (Cunnington et al., 2011) . Construction of the Meox1, Meox2 and Meox2 DNA-binding-deficient adenoviruses (Meox2DBDmt) was previously described (Douville et al., 2011) .
Protein isolation
Following treatment, cells were washed twice with PBS. RIPA lysis buffer containing protease inhibitor cocktail (Sigma) and phosphatase inhibitors (10 mmol/l NaF, 1 mmol/l sodium orthovanadate, and 20 mmol/l b-glycerophosphate) was used to lyse cells and, following mechanical scraping, cell lysates were incubated on ice for 1 hour. Lysates were sonicated for 3610 seconds and then centrifuged at 8765 g at 4˚C for 15 minutes. Supernatants were transferred to new tubes and protein assays performed using the bicinchoninic acid method (Smith et al., 1985) .
Western blot analysis
SDS-PAGE of 20-40 ug of protein was performed on 6-8% gels using SeeBlue Plus2 Pre-Stained Standard (Bio-Rad, Hercules, CA) molecular mass marker. Proteins were transferred to 0.45 mM polyvinylidene difluoride (PVDF) membrane and blocked in PBS with 0.2% Tween-20 (PBS-T) containing 10% skimmed milk for 1.5 hours at room temperature with constant shaking. Primary antibodies were diluted in PBS-T with 3% skimmed milk as follows: Zeb2 (1:1000) (Sigma), btubulin (1:5000) (Abcam, Cambridge, UK), a-smooth muscle actin (1:5000) (Sigma), eukaryotic elongation factor 2 (eEF2) (1:3000) (Cell Signaling, Danvers, MA), ED-A fibronectin (1:1000) (Chemicon, Temecula, CA), SMemb (1:1000) (Abcam), FLAG [M2] (1:10,000) (Sigma), Meox2 (1:1000) (Santa Cruz Biotechnology, Santa Cruz, CA), a-tubulin (1:2000) (Abcam). Membranes were incubated for 1.5 hours at room temperature or overnight at 4˚C with shaking. Secondary antibodies were horseradish peroxidase (HRP)-labeled antirabbit and HRP-labeled anti-mouse antibodies, which were diluted 1:10,000 with PBS-T with 3% skimmed milk and incubated for 1.5 hours at room temperature with shaking. Protein bands were visualized using ECL or ECL Plus (Amersham, Arlington Heights, IL) according to the manufacturer's instructions, and developed on X-ray film. Equal protein loading was confirmed using b-tubulin, a-tubulin or eEF2 staining following stripping and re-probing of the western blots.
RNA isolation
Cardiac fibroblasts or myofibroblasts in 100 mm dishes were harvested for RNA using GenElute Mammalian Total RNA miniprep kits (Sigma) or RNeasy Plus kits (Qiagen, Hilden, Germany) according to the manufacturer's instructions. RNA was diluted in 10 mM Tris-HCl (pH 7.5) and the absorbance at 260 nm (A 260 ) was used to determine RNA concentration. RNA purity was assessed using the ratio of absorbance at 260 nm to absorbance at 280 nm (A 260 /A 280 ).
qPCR Isolated RNA was treated with RQ1 RNase-Free DNase according to the manufacturer's instructions. One-step real-time PCR was performed using an iQ5 thermocycler (Bio-Rad, Hercules, CA) and BR 1-Step SYBR Green qRT-PCR kits (Quanta, Gaithersburg, MD). Relative gene quantification (2 2DDCT method) was performed whereby the mRNA expression levels of Meox1 and Meox2 were compared with the mRNA expression of Gapdh. Primer sets for Meox1 (amplicon, 123 bp): ratMEOX1forward, 59-tcgcccaccataactacctg-39; ratMEOX1reverse, 59-ccttcacacgcttccacttc-39; Meox2 (amplicon, 114 bp): ratMEOX2forward, 59-ttagcgggctctgctcaaac-39; ratMEOX2reverse, 59-ttcacgaaggtcccaaagtc-39; GAPDH (amplicon, 87 bp): GAPDH forward, 59-tgcaccaccaactgcttagc-39; GAPDH reverse, 59-ggcatggactgtggtcatgag-39. Parameters for qPCR amplification steps available upon request.
EdU cell-proliferation assay P3 myofibroblasts (40% confluent) were infected with Meox2 and LacZ adenovirus (50 and 100 MOI). Click-iT EdU flow cytometry assay kit (Invitrogen) was used to further investigate the effects of Meox2 on proliferation of primary rat myofibroblast. Briefly, 5-ethynyl-29-deoxyuridine (EdU) reagent was added at a 10 mM concentration 16 hours after infection and cells were harvested 8 hours later. Cells were collected, fixed and then incubated with saponin-based permeabilization buffer. Click-iT reaction cocktail containing copper sulphate and fluorescent dye azide (Alexa Fluor 488) was freshly prepared and added to the samples. EdU incorporation into DNA was assessed using flow cytometry. Simultaneously, cells were counted using a hemocytometer to confirm the EdU FACS assay (Movassagh et al., 2013 ).
Experimental rat model of MI and cellular fractionation
Experimental protocols for animal studies were approved by the Animal Care Committee of the University of Manitoba, Canada, and conform to the guidelines established by the Canadian Institutes of Health Research and the Canadian Council on Animal Care (2001). MI was induced in male Sprague-Dawley rats (150-175 g) by surgical occlusion of the left coronary artery, as described previously (Dixon et al., 1990) . The mortality of the animals operated on in this fashion was 30% within 48 hours. Experimental animals were sacrificed after 48 hours (acutely infarcted) and 2 or 4 weeks (chronically infarcted) post-MI, and cardiac tissues isolated from two, left ventricular (LV) regions: remnant/viable (non-infarcted) LV-free wall remote from the infarct scar and septum, and infarct scar. Infarcted (pale, necrotic tissue in acutely-infarcted versus overtly healed scar tissue in chronically infarcted animals) and non-infarcted regions were determined visually, and compared with the same regions obtained from sham-operated rats. Cardiac tissues from sham-operated LVs, viable LVs, and scar regions were homogenized in 100 mM Tris-HCl (pH 7.4) containing 1 mM EDTA, 1 mM phenylmethylsulfonyl fluoride, 4 mM leupeptin, 1 mM pepstatin, 0.3 mM aprotinin. This homogenate was sonicated for 56 5 seconds. To isolate the cytosolic fractions, the samples were centrifuged at 3000 g for 10 minutes at 4˚C. The resulting supernatant was further subjected to centrifugation at 48,000 g for 20 minutes at 4˚C (Cunnington et al., 2011) . The resulting supernatant was used for the cytosolic Meox2 and Zeb2 protein assays by western blot.
Statistics
Data were analyzed using SigmaStat software and are expressed as mean 6 s.e.m. Groups were compared using one-way ANOVA with StudentNewman-Keuls post-hoc test for multiple group comparisons. *P,0.05 unless otherwise indicated.
